7MM pulmonary arterial hypertension market to hit $9.3b by 2034
The treatment paradigm is shifting to proactive intervention.
The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM) is projected to reach $9.3b by 2034, according to GlobalData.
The sector’s expansion is attributed to the adoption of triple combination therapy, novel prostacyclin formulations, and the entry of disease-modifying therapies.
Moreover, the PAH treatment paradigm is shifting from reactive symptom management to proactive intervention, said Sulayman Patel, Senior Analyst in Cardiovascular & Metabolic Disorders at GlobalData.
“As disease-modifying therapies gain ground, success will require not just breakthrough science but seamless integration into real-world care,” Patel added.
7MM = US, France, Germany, Italy, Spain, UK, and Japan.
Read Here
Advertise
Sign Up
